03 dec: Indre værdi af SmallCap Danmark A/S er opgjort til 21,2 kr. pr. a..
03 dec: NTR Holding A/S: Finanskalender
03-12-2018 03:17:50

Genmab to Hold R&D Update and 2018 ASH Data Review Meeting

Media Release

  • Event to be held today in San Diego, California

  • Independent experts to discuss data presented at the 2018 ASH Annual Meeting

  • Meeting to be webcast live and archived on www.genmab.com

Copenhagen, Denmark; December 3, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) will hold a R&D Update and 2018 ASH Data Review Meeting today, December 3, 2016 at 8:00 PM Pacific Time (5:00 AM CET / 4:00 AM GMT on 4 December).  The event will take place in San Diego, California, and will also be webcast live and archived on the company’s website.  The meeting will include presentations by independent experts on data from daratumumab studies presented at the 60th Annual Meeting of the American Society of Hematology (ASH), including some key aspects of the Phase III MAIA study. Genmab speakers will also discuss pre-clinical data from Genmab’s DuoBody-CD3xCD20 and DuoHexaBody-CD37 programs presented at ASH, as well as the company’s progress and key goals for 2019.

The following cancer experts and senior Genmab staff will be at the event:

Independent experts:

  • Dr. Meletios A. Dimopoulos, National and Kapodistrian University of Athens, School of Medicine
  • Dr. Nizar Bahlis, Arnie Charbonneau Cancer Institute, University of Calgary
  • Dr. Saad Usmani, University of North Carolina at Chapel Hill, Levine Cancer Institute

Genmab:

  • Dr. Jan van de Winkel, President and CEO, Genmab
  • Dr. Judith Klimovsky, Executive Vice President and CDO, Genmab
  • Dr. Kate Sasser, Corporate Vice President, Translational Research, Genmab

Key daratumumab abstracts to be discussed during the event include:

LB-2: Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

Abstract 156: One-year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) With Transplant-ineligible Newly Diagnosed Multiple Myeloma (NDMM): ALCYONE

Abstract 151: Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from GRIFFIN, a Phase 2 Randomized Study of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Eligible for High-Dose Therapy and Autologous Stem Cell Transplantation

Abstract 1996: Three-Year Follow Up of the Phase 3 POLLUX Study of Daratumumab Plus Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma

Abstract 3270: Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib, and Dexamethasone in First Relapse Patients: Two-Year Update of CASTOR

Abstract 1995: Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-label, Multicenter, Phase 1b Study (PAVO)

The event will take place at the Manchester Grand Hyatt in San Diego, California, Harbor G&H. Those wishing to attend in person may register on site.

The event can also be attended via webcast. To view this webcast visit: https://edge.media-server.com/m6/p/8gdmxojt. Webcast viewers may submit questions during the Q&A portion of the live webcast via the webcast player. An archive of the webcast will be available on Genmab’s website. The webcast will be conducted in English.

This meeting is not an official program of the ASH Annual Meeting.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications and other blood cancers.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies and the HexElect™ platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products.  Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.

Contact:          

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communication

T: +45 33 44 77 20; E: rcg@genmab.com

This Media Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody™; HexElect™; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

Media Release no. 15

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Attachment

logo.jpg

Relateret indhold
22 mar - 
Genmab-partner søger om udvidet brug af Darzalex i Euro..
20 mar - 
Onsdagens aktier: FLSmidth med til at stoppe langvarig ..
20 mar - 
Aktier/middag: Udenlandske investorer får FLSmidth til ..
Relateret debat
22 mar - 
Den må da snart fise over de 1200, med den og de nu beg..
22 mar - 
Vil skyde på vi lukker i 1162.
22 mar - 
Mon ikke vi allerede idag skal lukke i pænt plus! God w..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
22 mar
GEN
Har aktien:   GENMAB: PARTNER SØGER OM UDVIDET BRUG AF DARZALEX I EUROPA 12:05Genmabs amerikanske pa..
7
20 mar
GEN
  Pengkom!  Det er et sådannne indlæg, som ødelægger en saglig debat. Jeg syntes det er pineligt, at..
6
22 mar
GEN
En godkendelse i USA er lige om hjørnet. Der er KÆMPE chance for en godkendelse - dette ved vi efter..
5
20 mar
GEN
Der er kommet recepttal for februar og Venetoclax i problemer i MM, så formodentlig det der løfter a..
4
22 mar
GEN
Den må da snart fise over de 1200, med den og de nu begge snarlige godkendelser!
3
22 mar
GEN
Vil skyde på vi lukker i 1162.
3
20 mar
GEN
Den burde være i min 1500 kr nu, men det kommer bare på en voldsom måde når det sker. Har Genmab og ..
3
20 mar
GEN
Tre kandidater:   Zymeworks (primært bispecifikke antistofs baseret med god platform - middel risiko..
3
22 mar
GEN
Mon ikke vi allerede idag skal lukke i pænt plus!   God weekend!
2
21 mar
GEN
Der skal nok komme de stigninger jeg forventer, de kommer bare ikke når man venter dem. Tag det roli..
2

Lars Christensens Verden - Episode 12: Bankernes rolle i samfundet

22-03-2019 07:12:24
I ”Lars Christensens Verden” går økonom og chefredaktør på Euroinvestor Lars Christensen bag om markedet i samtaler med professionelle markedsaktører, kommentatorer og økonomiske og finansielle forskere. Det handler om, hvad det i virkeligheden er, der driver de finansielle markeder. Det er ikke investeringsråd, men mottoet er, at den, der ved mest, tjener mest. Det leveres alt sammen med humor og..

Recessionsfrygt i obligationsmarkedet

Relaterede nyheder
22-03-2019 15:08:12
Rentemarkederne har i dag sendt flere signaler, som analytikere betegner som klare signaler om lavere vækst og måske endda recession.Således faldt den tyske 10-årige statsobligationsrente i dag under 0 pct., hvilket afspejler investorernes frygt for den europæiske vækst. Tal, der viser indkøbschefernes forventninger til fremtiden, de såkaldte PMI-tal, faldt kraftigere end ventet i marts i flere eu..

Tysk 10-års rente falder under 0 pct. – "Gassen er gået af ballonen"

Relaterede nyheder
22-03-2019 11:26:06
De tyske PMI-tal, som i dag blev i dag offentliggjort, faldt til 44,7 fra 47,6 og rammer dermed laveste niveau siden september 2012. I en kommentar til Euroinvestor udtaler makroanalytiker i Sydbank, Mathias Rømer Sproegel: "Dagens læsning af de tyske PMI’er var ikke rar læsning for investorerne. Bekymringer om Brexit, den globale handelskrig mellem USA og Kina samt fortsat store problemer i den t..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Genmab A/S 1.153,00 0,0% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. marts 2019 06:36:44
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190320.1 - EUROWEB4 - 2019-03-24 06:36:44 - 2019-03-24 06:36:44 - 1 - Website: OKAY